1. Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approach
- Author
-
Md. Tabassum Hossain Emon, Mohammad Uzzal Hossain, Md. Golam Mosaib, Zeshan Mahmud Chowdhury, Chaman Ara Keya, Arittra Bhattacharjee, Muntahi Mourin, Md. Salimullah, and Keshob Chandra Das
- Subjects
Gene Expression Regulation, Viral ,0301 basic medicine ,Coronavirus M Proteins ,viruses ,In silico ,Computational biology ,Biology ,Genome sequencing ,medicine.disease_cause ,Antiviral Agents ,Genome ,DNA sequencing ,Conserved sequence ,03 medical and health sciences ,0302 clinical medicine ,Chimeric vaccine ,medicine ,Genetics ,Humans ,Gene silencing ,Computer Simulation ,Prospective Studies ,Gene ,Conserved Sequence ,Small molecule drugs ,Coronavirus ,Whole genome sequencing ,Whole Genome Sequencing ,SARS-CoV-2 ,Sequence Analysis, RNA ,Gene Expression Profiling ,fungi ,COVID-19 ,Computational Biology ,General Medicine ,Middle Aged ,RNA-Dependent RNA Polymerase ,COVID-19 Drug Treatment ,siRNAs ,030104 developmental biology ,Drug Design ,030220 oncology & carcinogenesis ,Spike Glycoprotein, Coronavirus ,Female ,Interferons ,Research Paper - Abstract
Highlights • RNA-dependent RNA polymerase (RdRp), Spike (S) and glycoprotein (M) were selected. • Both S and M were chosen for the development of a chimeric vaccine. • siRNAs were also designed for S and M gene silencing. • Six new drug candidates were suggested that might inhibit the activity of RdRp., Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has become an immense threat to global public health. In this study, we performed complete genome sequencing of a SARS-CoV-2 isolate. More than 67,000 genome sequences were further inspected from Global Initiative on Sharing All Influenza Data (GISAID). Using several in silico techniques, we proposed prospective therapeutics against this virus. Through meticulous analysis, several conserved and therapeutically suitable regions of SARS-CoV-2 such as RNA-dependent RNA polymerase (RdRp), Spike (S) and Membrane glycoprotein (M) coding genes were selected. Both S and M were chosen for the development of a chimeric vaccine that can generate memory B and T cells. siRNAs were also designed for S and M gene silencing. Moreover, six new drug candidates were suggested that might inhibit the activity of RdRp. Since SARS-CoV-2 and SARS-CoV-1 have 82.30% sequence identity, a Gene Expression Omnibus (GEO) dataset of Severe Acute Respiratory Syndrome (SARS) patients were analyzed. In this analysis, 13 immunoregulatory genes were found that can be used to develop type 1 interferon (IFN) based therapy. The proposed vaccine, siRNAs, drugs and IFN based analysis of this study will accelerate the development of new treatments.
- Published
- 2021
- Full Text
- View/download PDF